Friday July 17, 2015 0 comments
BOULDER -- PanTheryx Inc., a global medical nutrition company based in Boulder, announced its flagship product for pediatric infectious diarrhea – DiaResQ – has been selected as one of 30 leading health care innovations with great promise to transform global health by 2030.
The selection was announced in Reimagining Global Health, the inaugural report of the Innovation Countdown 2030 Initiative.
DiResQ was one of only 12 innovations recognized in the maternal, newborn and child health categories, the company said.
DiaResQ is specifically formulated for the dietary needs of children with infectious diarrhea and promotes intestinal repair while boosting a child’s natural defenses, PanTheryx said.
“We are truly honored to have DiaResQ included in the Innovation Countdown 2030’s Reimagining Global Health Report,” said Mark A. Braman, PanTheryx president and CEO.
“This recognition validates what we have always believed – that DiaResQ is truly a breakthrough nutritional intervention for pediatric diarrhea with the potential to greatly improve the well-being and quality-of-life of millions of children and their families worldwide.”
Globally, infectious diarrhea affects about 1.7 billion children under five each year with almost 760,000 deaths.
Led by PATH and supported by the Norwegian Agency for Development Cooperation, the Bill & Melinda Gates Foundation and United States Agency for International Development, the Innovation Countdown 2030 Initiative aims to accelerate high-potential innovations, catalyzing investment and increasing awareness of and support for transformative ideas to improve health and save lives.